$1.62
0.62% today
NYSE, Sep 17, 10:00 pm CET
ISIN
US68218J1034
Symbol
OABI

OmniAb Stock price

$1.61
-0.40 19.90% 1M
-1.56 49.21% 6M
-1.93 54.52% YTD
-2.95 64.69% 1Y
-8.57 84.18% 3Y
-8.39 83.90% 5Y
-8.39 83.90% 10Y
-8.39 83.90% 20Y
NYSE, Closing price Tue, Sep 16 2025
+0.00 0.00%

Key metrics

Basic
Market capitalization
$197.6m
Enterprise Value
$155.9m
Net debt
positive
Cash
$41.6m
Shares outstanding
122.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.6 | 8.9
EV/Sales
6.8 | 7.0
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
88.4%
Return on Equity
-21.6%
ROCE
-26.0%
ROIC
-27.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$23.0m | $22.2m
EBITDA
$-57.8m | $-51.8m
EBIT
$-73.7m | $-67.0m
Net Income
$-63.5m | $-73.4m
Free Cash Flow
$-32.0m
Growth (TTM | estimate)
Revenue
6.0% | -15.9%
EBITDA
11.9% | 9.4%
EBIT
8.3% | 10.0%
Net Income
-1.8% | -18.3%
Free Cash Flow
31.6%
Margin (TTM | estimate)
Gross
15.8%
EBITDA
-251.0% | -233.1%
EBIT
-320.1%
Net
-275.8% | -330.5%
Free Cash Flow
-139.1%
More
EPS
$-0.6
FCF per Share
$-0.3
Short interest
6.7%
Employees
114
Rev per Employee
$230.0k
Show more

Is OmniAb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

OmniAb Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a OmniAb forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a OmniAb forecast:

Buy
93%
Hold
7%

Financial data from OmniAb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
23 23
6% 6%
100%
- Direct Costs 0.26 0.26
-
1%
3.64 3.64
-
16%
- Selling and Administrative Expenses 30 30
8% 8%
130%
- Research and Development Expense 50 50
12% 12%
217%
-58 -58
12% 12%
-251%
- Depreciation and Amortization 16 16
8% 8%
69%
EBIT (Operating Income) EBIT -74 -74
8% 8%
-320%
Net Profit -64 -64
2% 2%
-276%

In millions USD.

Don't miss a Thing! We will send you all news about OmniAb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OmniAb Stock News

Neutral
Business Wire
15 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9th with investors registered for the event. Investors int...
Neutral
Business Wire
23 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the pri...
Neutral
Seeking Alpha
about one month ago
OmniAb, Inc. (NASDAQ:OABI ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kurt A. Gustafson - Executive VP of Finance & CFO Matthew W.
More OmniAb News

Company Profile

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Head office United States
CEO Matthew Foehr
Employees 114
Founded 2015
Website www.omniab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today